Study Adds Pembrolizumab to Paradigm for Certain Head and Neck Cancers
July 24th 2015
A group of researchers at Washington University in St. Louis recently opened a clinical trial to evaluate pembrolizumab as treatment intensification therapy for patients with high-risk locoregionally advanced, previously untreated, HPV-negative head and neck squamous cell carcinomas.